SI1734992T1 - Izboljšana inaktivirana FCV cepiva - Google Patents

Izboljšana inaktivirana FCV cepiva

Info

Publication number
SI1734992T1
SI1734992T1 SI200531433T SI200531433T SI1734992T1 SI 1734992 T1 SI1734992 T1 SI 1734992T1 SI 200531433 T SI200531433 T SI 200531433T SI 200531433 T SI200531433 T SI 200531433T SI 1734992 T1 SI1734992 T1 SI 1734992T1
Authority
SI
Slovenia
Prior art keywords
fcv
improved
vaccines
inactivated
inactivated fcv
Prior art date
Application number
SI200531433T
Other languages
English (en)
Inventor
Herve Poulet
Denis Barral
Original Assignee
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd filed Critical Merial Ltd
Publication of SI1734992T1 publication Critical patent/SI1734992T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16061—Methods of inactivation or attenuation
    • C12N2770/16063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SI200531433T 2004-01-21 2005-01-19 Izboljšana inaktivirana FCV cepiva SI1734992T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53784904P 2004-01-21 2004-01-21
EP05705920A EP1734992B1 (en) 2004-01-21 2005-01-19 Improved inactivated fcv vaccines
PCT/US2005/001721 WO2005072214A2 (en) 2004-01-21 2005-01-19 Improved inactivated fcv vaccines

Publications (1)

Publication Number Publication Date
SI1734992T1 true SI1734992T1 (sl) 2012-01-31

Family

ID=34825947

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200531433T SI1734992T1 (sl) 2004-01-21 2005-01-19 Izboljšana inaktivirana FCV cepiva

Country Status (13)

Country Link
EP (1) EP1734992B1 (sl)
JP (1) JP4873632B2 (sl)
CN (1) CN1933852A (sl)
AT (1) ATE526034T1 (sl)
CA (1) CA2553805C (sl)
CY (1) CY1112575T1 (sl)
DK (1) DK1734992T3 (sl)
ES (1) ES2374549T3 (sl)
HK (1) HK1095035A1 (sl)
PL (1) PL1734992T3 (sl)
PT (1) PT1734992E (sl)
SI (1) SI1734992T1 (sl)
WO (1) WO2005072214A2 (sl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7850978B2 (en) * 1999-07-16 2010-12-14 Merial Limited Vaccine against feline calicivirus
CN101461941B (zh) * 2007-12-20 2012-07-04 施怀哲维克有限公司 疫苗及其制备方法
CN103773739B (zh) * 2013-03-01 2016-06-15 上海启盛生物科技有限公司 一种猫泛白细胞减少症病毒减毒疫苗株及其应用
JP6395855B2 (ja) 2014-04-03 2018-09-26 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド ブタ流行性下痢ウイルスワクチン
CN108473539B (zh) * 2015-12-23 2022-03-22 英特维特国际股份有限公司 猫杯状病毒疫苗
RO132299A3 (ro) * 2017-06-06 2018-12-28 Fântână Raul Sorin Compoziţie şi metodă de preparare şi evaluare a unui imunogen complex numit i-spga, destinat producerii de proteine imunologic active ()
CN112877297A (zh) * 2021-03-27 2021-06-01 哈尔滨元亨生物药业有限公司 一种利用生物反应器制备猫瘟热病毒单克隆抗体的方法
CN114107170B (zh) * 2021-11-12 2023-08-29 广东省华晟生物技术有限公司 猫肾悬浮细胞系及其构建方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
WO2000076538A1 (en) * 1999-06-10 2000-12-21 Michigan State University Feline calicivirus isolated from cat urine and vaccines thereof
US6534066B1 (en) * 1999-07-16 2003-03-18 Merial Inactivated vaccine against feline calicivirosis
FR2796282B1 (fr) * 1999-07-16 2001-10-26 Merial Sas Vaccin inactive contre la calicivirose feline
ATE384786T1 (de) * 1999-12-20 2008-02-15 Agricultural Research Council Verfahren zur inaktivierung von mikroorganismen

Also Published As

Publication number Publication date
WO2005072214A3 (en) 2006-09-28
EP1734992A4 (en) 2009-01-21
CY1112575T1 (el) 2016-02-10
DK1734992T3 (da) 2011-12-05
WO2005072214A2 (en) 2005-08-11
PL1734992T3 (pl) 2012-02-29
JP4873632B2 (ja) 2012-02-08
CA2553805A1 (en) 2005-08-11
ES2374549T3 (es) 2012-02-17
CN1933852A (zh) 2007-03-21
JP2007522127A (ja) 2007-08-09
EP1734992A2 (en) 2006-12-27
HK1095035A1 (en) 2007-04-20
CA2553805C (en) 2013-05-21
PT1734992E (pt) 2011-12-21
EP1734992B1 (en) 2011-09-28
ATE526034T1 (de) 2011-10-15

Similar Documents

Publication Publication Date Title
CY1112575T1 (el) Βελτιωμενα αδρανοποιημενα εμβολια fcv
TW200806316A (en) Yeast-based vaccine for inducing an immune response
MY149604A (en) C.perfringens alpha toxoid vaccine
PL1635863T3 (pl) Kompozycje do wywoływania, wzmacniania i utrzymywania odpowiedzi immunologicznych na epitopy ograniczone do MHC klasy I do celów profilaktycznych i leczniczych
PH12014501836A1 (en) Novel adjuvant compositions
WO2007024941A3 (en) Polyvalent vaccine
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
MY155236A (en) Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant
ZA200701176B (en) Vaccines against aids comprising CMV/R-nucleic acid constructs
MX2022009167A (es) Formulaciones para vacuna contra coronavirus.
MY161965A (en) New influenza virus immunizing epitope
MX2009006178A (es) Vacuna contra salmonela.
WO2006063053A3 (en) Methods of producing influenza vaccine compositions
SG158154A1 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
WO2009034315A3 (en) Vaccine
CA2763359C (en) New human rotavirus strains and vaccines
WO2008127296A3 (en) Methods and compositions for treating tularemia
WO2002087494A3 (en) Novel vaccine
WO2008148057A3 (en) Cationic lipids compositions and methods for enhancing immune responses to vaccines
ZA200710011B (en) A method for preparing a stable immunogenic product comprising antigenic heterocomplexes of TNFα and a carrier protein
WO2003066094A3 (en) Hepatitis b vaccines
DE60336588D1 (de) Verbesserte anthraximpfstoffe und abgabeverfahren
WO2003060088A3 (en) Viral vaccine production method
AU2003278175A8 (en) Vaccines of enhanced immunogenicity, and methods for preparing such vaccines
WO2005123112A3 (en) Method of enhancing the immune response to a vaccine